- Home
- DEA vs DVAX Comparison
DEA vs DVAX Comparison
Compare DEA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- DVAX
- Stock Information
- Founded
- DEA 2011
- DVAX 1996
- Country
- DEA United States
- DVAX United States
- Employees
- DEA N/A
- DVAX N/A
- Industry
- DEA Real Estate Investment Trusts
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- DVAX Health Care
- Exchange
- DEA Nasdaq
- DVAX Nasdaq
- Market Cap
- DEA 1.3B
- DVAX 1.5B
- IPO Year
- DEA 2015
- DVAX 2004
- Fundamental
- Price
- DEA $12.48
- DVAX $12.36
- Analyst Decision
- DEA Buy
- DVAX Buy
- Analyst Count
- DEA 2
- DVAX 2
- Target Price
- DEA $14.50
- DVAX $22.00
- AVG Volume (30 Days)
- DEA 1.4M
- DVAX 3.0M
- Earning Date
- DEA 11-05-2024
- DVAX 11-07-2024
- Dividend Yield
- DEA 8.49%
- DVAX N/A
- EPS Growth
- DEA N/A
- DVAX N/A
- EPS
- DEA 0.17
- DVAX 0.15
- Revenue
- DEA $302,121,000.00
- DVAX $260,810,000.00
- Revenue This Year
- DEA N/A
- DVAX $23.13
- Revenue Next Year
- DEA $7.29
- DVAX $19.60
- P/E Ratio
- DEA $73.61
- DVAX $81.69
- Revenue Growth
- DEA 2.98
- DVAX N/A
- 52 Week Low
- DEA $10.94
- DVAX $9.74
- 52 Week High
- DEA $14.53
- DVAX $15.01
- Technical
- Relative Strength Index (RSI)
- DEA 36.39
- DVAX 54.02
- Support Level
- DEA $11.53
- DVAX $11.51
- Resistance Level
- DEA $13.67
- DVAX $13.74
- Average True Range (ATR)
- DEA 0.37
- DVAX 0.58
- MACD
- DEA -0.12
- DVAX -0.10
- Stochastic Oscillator
- DEA 42.19
- DVAX 35.71
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.